In this study, we tested the efficacy and safety of donor lymphocyte infusion (DLI) with granulocyte colony-stimulating factor (G-CSF) priming in patients who relapsed after haploidentical hematopoietic stem cell transplantation (HSCT). Twenty patients received DLI at a median of 177 days after HSCT. Eight patients survived in complete remission for a median of 1118 days. The 2-year probability of leukemia-free survival was 40%. Acute graft-versus-host disease (GVHD) grade 3-4 occurred in six patients after DLI. GVHD prophylaxis reduced the incidence of acute GVHD. Our primary data showed that G-CSF-primed DLI with GVHD prophylaxis was a potentially effective therapeutic option for patients who relapsed after haploidentical HSCT. 's Hospital, Beijing, 100044, China E-mail: xjhrm@medmail.com.cn 
D
onor lymphocyte infusion (DLI) has been shown to exert a graft-versusleukemia (GVL) effect and has been successfully used for the treatment of leukemia relapse in patients who have undergone HLA-matched, related or unrelated hematopoietic stem cell transplantation (HSCT).
1,2 Granulocyte colony-stimulating factor (G-CSF)-primed DLI might achieve a comparable or stronger GVL effect than that of the infusion of non-mobilized lymphocytes. 3 Furthermore, graft-versus-host disease (GVHD) prophylaxis might reduce the occurrence of fatal GVHD after DLI. 4 So far, there is little published information on the efficacy and toxicity of DLI in an HLA-mismatched setting. 5, 6 In the present study, G-CSF mobilization and GVHD prophylaxis were applied to DLI in haploidentical transplantation, and the safety and efficacy of this treatment strategy was evaluated.
Design and Methods

Patients
Twenty patients who underwent haploidentical T-cell-replete HSCT between April 1, 2002, and May 1, 2005, and then relapsed were included. The characteristics of these 20 patients are summarized in Table 1 .
Transplantation procedure
The transplantation procedure, including the conditioning regimens, donor priming, graft harvest and GVHD prophylaxis, was as described recently.
7
Definitions
Hematologic relapse of leukemia after transplantation was defined as the recurrence of signs and symptoms of leukemia. In chronic myeloid leukemia (CML), cytogenetic relapse was defined as the recurrence of metaphases with the Philadelphia chromosome (Ph + ) without hematologic or clinical features of CML. Complete or partial responses were evaluable in patients who survived at least 30 days after DLI because the earliest examination of bone marrow morphology was done 4 weeks after the reinfusion. The severity of acute and chronic GVHD was determined according to the criteria described by Glucksberg et al. 8 However, GVHD was diagnosed as acute or chronic according to clinical features of the affected organs rather than time after DLI. 
Donor lymphocyte infusion
Lymphocytes were obtained from cryopreserved G-CSF-mobilized peripheral blood (G-PB) or from fresh G-PB. The Peking University Review Board approved the cryopreservation, remobilization and infusion of the G-PB. All donors and patients signed a consent form. DLI doses were defined as CD3 cells per kilogram of recipient weight. Immunosuppressive agents were discontinued if patients were still receiving them when the leukemia relapse was diagnosed. However, after DLI 12 patients received cyclosporine A (blood concentration of 150-250 ng/mL for 2-4 weeks) or a low dose of methotrexate (10 mg once per week for 2-4 weeks) for prophylaxis against GVHD.
Statistical analysis
Time to GVHD after DLI was defined as the time from DLI to the onset of any grade of GVHD. The cumulative incidence of acute and chronic GVHD after DLI was calculated with competing risks of relapse and death. Distributions for time-to-relapse, time-to-complete remission, and actual leukemia-free survival were evaluated using Kaplan-Meier analysis. The surviving patients were followed up, and the results of follow-up were analyzed on June 30, 2006. Unless otherwise specified, all reported p values were based on two-sided hypothesis tests.
Results and Discussion
Relapse after transplantation
Twenty patients (Table 1) /day for 5 days). Two patients, one with Ph + acute lymphoblastic leukemia, the other with CML in blastic phase, were given imatinib (300-400 mg/day) for 22 or 89 days, respectively, and the patient with CML achieved complete remission. Nine patients received DLI without any prior intervention.
Response to donor lymphocyte infusion
A total of 27 infusions were given to 20 patients a median of 177 (46-750) days after HSCT. The cell subsets infused for transplantation and DLI are shown in Table 2 . Eight patients survived without recurrence of their original leukemia through the end of follow-up, with a median follow-up of 1118 (range, 754-1468) days after HSCT and 808 days (range, 627-1388) days after DLI. The 1-year and 2-year probabilities of leukemia-free survival were 60 and 40%, respectively. Fifteen patients achieved complete remission at a median of 289 (40-1388) days after DLI. Five of these fifteen patients were in the group that did not receive prophylaxis for GVHD after DLI, and the other ten patients were in the group that did receive prophylaxis. The blast count in bone marrow at the time of relapse was a risk factor influencing survival. The difference in bone marrow blast count at relapse between the group of patients who remained free of leukemia and the group of patients who subsequently died (6.0% versus 20.0%, respectively) was statistically significant (p=0.001). No extensive chronic GVHD occurred in the non-remission group; Seven of the 15 cases of extensive chronic GVHD occurred in the group of patients who achieved complete remission after DLI (p=0.046). However, this chronic GVHD was not found to influence survival.
GVHD and pancytopenia
Acute GVHD grades 1-2 occurred in five patients, and acute GVHD grades 3-4 occurred in six patients. In the initial nine patients studied, no GVHD prophylaxis was given after DLI. Five patients developed acute GVHD grades 3-4. In the eleven patients studied later, GVHD prophylaxis was applied, and only one developed acute GVHD grades III-IV (p=0.013, Figure 1 ). Chronic GVHD occurred in seven patients with a cumulative incidence of 64% at a median of 289 (40-1388) days after DLI, and six patients had the extensive type of GVHD.
The nadir of the white blood cell count occurred 48.5 (14-71) days after DLI, and that of the platelet count 48.5 (18-71) days after DLI. The white blood cell count decreased to less than 2.0×10 9 /L in four patients and to Figure 1 . The influence of GVHD prophylaxis on occurrence of GVHD. In the initial nine patients studied, no GVHD prophylaxis was given after DLI. Five of these nine patients developed acute GVHD grades III-IV. In the eleven patients studied later, GVHD prophylaxis was given, and only one developed acute GVHD grades III-IV (p=0.0128) 
